[go: up one dir, main page]

CN113164586A - 免疫组合物及其制备方法与应用 - Google Patents

免疫组合物及其制备方法与应用 Download PDF

Info

Publication number
CN113164586A
CN113164586A CN201980063806.6A CN201980063806A CN113164586A CN 113164586 A CN113164586 A CN 113164586A CN 201980063806 A CN201980063806 A CN 201980063806A CN 113164586 A CN113164586 A CN 113164586A
Authority
CN
China
Prior art keywords
flagellin
vector
seq
immunogenic composition
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980063806.6A
Other languages
English (en)
Other versions
CN113164586B (zh
Inventor
慕婷
赵萍
徐龙
肖杨
朱利安·琼·菲利普
吴月
谢亮
陈雪婷
刘奇
谢铎源
庄再成
克莱因·米歇尔
杜林森
吴克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan BravoVax Co Ltd
Original Assignee
Wuhan BravoVax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan BravoVax Co Ltd filed Critical Wuhan BravoVax Co Ltd
Publication of CN113164586A publication Critical patent/CN113164586A/zh
Application granted granted Critical
Publication of CN113164586B publication Critical patent/CN113164586B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明提供了一种免疫组合物及其制备方法与应用。本发明通过原核表达体系或重组腺病毒体系高效表达VZV包膜gE糖蛋白及其gE鞭毛素融合蛋白。将制得的重组gE蛋白、gE鞭毛素融合蛋白及重组腺病毒载体或其组合物免疫小鼠后可刺激机体产生gE和VZV特异性抗体滴度及gE和VZV特异性的细胞免疫。

Description

PCT国内申请，说明书已公开。

Claims (64)

  1. PCT国内申请，权利要求书已公开。
CN201980063806.6A 2018-09-27 2019-09-12 免疫组合物及其制备方法与应用 Active CN113164586B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201811131501 2018-09-27
CN2018111315018 2018-09-27
CN2019105718393 2019-06-28
CN201910571839 2019-06-28
PCT/CN2019/105716 WO2020063370A2 (zh) 2018-09-27 2019-09-12 免疫组合物及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN113164586A true CN113164586A (zh) 2021-07-23
CN113164586B CN113164586B (zh) 2024-04-16

Family

ID=69953299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980063806.6A Active CN113164586B (zh) 2018-09-27 2019-09-12 免疫组合物及其制备方法与应用

Country Status (6)

Country Link
US (1) US20210290759A1 (zh)
EP (1) EP3868399A4 (zh)
CN (1) CN113164586B (zh)
AU (1) AU2019349036A1 (zh)
CA (1) CA3114658A1 (zh)
WO (1) WO2020063370A2 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114163503A (zh) * 2021-12-15 2022-03-11 北京交通大学 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用
CN115819616A (zh) * 2021-07-28 2023-03-21 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
CN116023510A (zh) * 2022-12-01 2023-04-28 北京吉诺卫生物科技有限公司 双佐剂重组带状疱疹疫苗
CN116143949A (zh) * 2023-02-23 2023-05-23 中山大学 一种水痘-带状疱疹病毒疫苗及其制备方法
CN116350770A (zh) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2023179588A1 (zh) * 2022-03-21 2023-09-28 厦门大学 截短的水痘-带状疱疹病毒囊膜糖蛋白gE

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818084D0 (en) * 2018-11-06 2018-12-19 Univ Oxford Innovation Ltd Compositions and methods
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN110343722A (zh) * 2019-07-03 2019-10-18 上海大学 一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法
EP4212173A4 (en) * 2020-09-11 2024-10-23 Eubiologics Co., Ltd. Vaccine composition for chickenpox or varicella zoster and method of using same
CN112552380B (zh) * 2020-12-10 2021-12-24 武汉博沃生物科技有限公司 一种SARS-CoV-2病毒的免疫原及其应用
TWI782542B (zh) * 2021-05-25 2022-11-01 國立屏東科技大學 一種鞭毛蛋白的重組蛋白及其用途
EP4615498A1 (en) * 2022-11-08 2025-09-17 Vernagen, LLC Engineered varicella zoster virus shingles mrna vaccine
CN119080948B (zh) * 2023-04-17 2025-05-27 北京康乐卫士生物技术股份有限公司 带状疱疹病毒疫苗的嵌合抗原及其应用
CN117100850B (zh) * 2023-06-04 2025-07-25 北京智飞绿竹生物制药有限公司 一种用于水痘-带状疱疹病毒感染的重组腺病毒疫苗
CN117003894B (zh) * 2023-08-09 2024-04-16 成都新诺明生物科技有限公司 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用
CN119113100B (zh) * 2024-09-26 2025-11-25 江苏立维斯德生物技术有限公司 一种重组带状疱疹疫苗组合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189254A (zh) * 2005-03-03 2008-05-28 葛兰素史密丝克莱恩生物有限公司 疫苗
CN103827131A (zh) * 2011-01-31 2014-05-28 宾夕法尼亚大学托管会 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
US20140161836A1 (en) * 2011-12-23 2014-06-12 Wuhan Institute Of Virology, Chinese Academy Of Sciences Carious tooth vaccine and preparation method
CN105906721A (zh) * 2016-06-21 2016-08-31 芜湖天明生物技术有限公司 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
WO2018124615A1 (ko) * 2016-12-26 2018-07-05 재단법인 목암생명과학연구소 대상포진 백신 조성물
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
DK2300609T3 (da) 2008-06-25 2014-02-10 Inst Nat Sante Rech Med Hidtil ukendt flagellinbaserede immunadjuvansforbindelser samt anvendelse deraf
CN102002098B (zh) * 2009-11-27 2013-07-24 中国科学院武汉病毒研究所 一种改造的鞭毛素蛋白及其制备方法和应用
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
WO2013074501A1 (en) * 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
CN103861101B (zh) * 2014-03-12 2016-04-27 中国药科大学 一种幽门螺杆菌多表位疫苗的新型嵌合鞭毛蛋白佐剂
CN107207614B (zh) * 2014-10-09 2022-01-11 利普泰克有限公司 嵌合蛋白
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
JP6367783B2 (ja) * 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189254A (zh) * 2005-03-03 2008-05-28 葛兰素史密丝克莱恩生物有限公司 疫苗
CN103827131A (zh) * 2011-01-31 2014-05-28 宾夕法尼亚大学托管会 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
US20140161836A1 (en) * 2011-12-23 2014-06-12 Wuhan Institute Of Virology, Chinese Academy Of Sciences Carious tooth vaccine and preparation method
CN105906721A (zh) * 2016-06-21 2016-08-31 芜湖天明生物技术有限公司 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
WO2018124615A1 (ko) * 2016-12-26 2018-07-05 재단법인 목암생명과학연구소 대상포진 백신 조성물
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAJOUA DENDOUGA等: "Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice", 《VACCINE》, vol. 30, no. 20, pages 3126 - 3135, XP055068453, DOI: 10.1016/j.vaccine.2012.01.088 *
李福民: "水痘—带状疱疹病毒糖蛋白E DNA疫苗的免疫原性研究", 《中国优秀博士学位论文全文数据库医药卫生科技辑》, no. 2, pages 059 - 30 *
瘳勇梅等: "水痘-带状疱疹病毒糖蛋白E真核表达载体的构建与鉴定", 《泸州医学院学报》, no. 4, pages 307 - 309 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819616A (zh) * 2021-07-28 2023-03-21 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
CN114163503A (zh) * 2021-12-15 2022-03-11 北京交通大学 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用
CN114163503B (zh) * 2021-12-15 2023-11-24 北京交通大学 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用
CN116350770A (zh) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2023179588A1 (zh) * 2022-03-21 2023-09-28 厦门大学 截短的水痘-带状疱疹病毒囊膜糖蛋白gE
CN116023510A (zh) * 2022-12-01 2023-04-28 北京吉诺卫生物科技有限公司 双佐剂重组带状疱疹疫苗
CN116023510B (zh) * 2022-12-01 2023-09-22 北京吉诺卫生物科技有限公司 双佐剂重组带状疱疹疫苗
CN116143949A (zh) * 2023-02-23 2023-05-23 中山大学 一种水痘-带状疱疹病毒疫苗及其制备方法

Also Published As

Publication number Publication date
WO2020063370A3 (zh) 2020-05-22
EP3868399A4 (en) 2022-07-20
AU2019349036A1 (en) 2021-06-03
EP3868399A2 (en) 2021-08-25
US20210290759A1 (en) 2021-09-23
WO2020063370A2 (zh) 2020-04-02
CA3114658A1 (en) 2020-04-02
CN113164586B (zh) 2024-04-16
WO2020063370A4 (zh) 2020-06-25
AU2019349036A8 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US20210290759A1 (en) Immune composition, preparation method therefor, and application thereof
CN113151184B (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US11229692B2 (en) Methods and compositions for inducing protective immunity against RSV infection
US20250228927A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
CN105906721A (zh) 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
US20230330214A1 (en) Improved dna vaccine for sars-cov-2
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
US10117923B2 (en) Production of an immunogen using a plant virus
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
CN119639781A (zh) 一种广谱甲型流感疫苗免疫原组合物及应用
Toussaint et al. Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8
EP2632941A2 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
CN113801206B (zh) 利用受体识别域诱导抗新冠病毒中和抗体的方法
US20220275346A1 (en) Hantavirus antigenic composition
US20240197865A1 (en) Compositions and methods for preventing rsv and piv3 infections
WO2023207717A1 (zh) H5n8禽流感广谱性疫苗的开发及其应用
CN116904489A (zh) 一种鸭坦布苏病毒核酸疫苗及应用
WO2023010176A1 (en) Vaccine construct and uses thereof
EP3202780A1 (en) Fusion protein comprising the n protein of a virus of the pneumovirinae subfamily
KR101366702B1 (ko) 호흡기 신시치아 바이러스 백신 조성물 및 그의 제조방법
WO2022127820A1 (zh) 病原样抗原疫苗及其制备方法
US20150274784A1 (en) Production of an Immunogen Using a Plant Virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 430075 bowo biological building, biomedical industrial park, 858 Gaoxin Avenue, Wuhan City, Hubei Province

Applicant after: BRAVOVAX Co.,Ltd.

Address before: 430075 Liang Jin, bowo biological building, biomedical industrial park, 858 Gaoxin Avenue, Wuhan City, Hubei Province

Applicant before: BRAVOVAX Co.,Ltd.

GR01 Patent grant
GR01 Patent grant